ReShape Lifesciences Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul F. Hickey
- Full Time Employees
- 17
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1001 Calle Amanecer San Clemente CA United States of America 92673
- IPO Date
- Oct 6, 2016
- CIK
- 0001427570
- Website
- reshapelifesciences.com
- Similar Companies
- Business
- ReShape Lifesciences Inc. is a premier weight loss and metabolic health solutions company founded in 2009 and headquartered in Irvine, California. The company provides an integrated portfolio of physician-led products and services designed to manage and treat obesity and metabolic diseases primarily in the United States, with additional operations in Australia, Europe, and internationally. Its main products include the FDA-approved Lap-Band System, which offers a minimally invasive, adjustable, long-term treatment for severe obesity as an alternative to more invasive surgical procedures like gastric bypass and sleeve gastrectomy; the Obalon Gastric Balloon System, a non-surgical, swallowable, gas-filled intra-gastric balloon designed for sustained weight loss; and the investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system, which uses proprietary vagus nerve block and stimulation technology aimed at treating type 2 diabetes and metabolic disorders. In 2024 and 2025, ReShape Lifesciences underwent significant strategic transformations, including entering into a definitive all-stock merger agreement with Vyome Therapeutics, a clinical-stage company focused on immuno-inflammatory and rare diseases. This merger, approved by shareholders in mid-2025, was completed in August 2025, with the combined entity expected to trade on Nasdaq under the name Vyome Holdings, Inc. and ticker symbol "HIND." Concurrently, ReShape entered into an asset purchase agreement to sell substantially all of its core assets—including the Lap-Band System, Obalon Gastric Balloon System, and DBSN System—to Biorad Medisys, which assumed related liabilities. These transactions represent a major strategic shift as ReShape exits its core weight loss and metabolic health business to focus on the merger and align with Vyome's ambitions in the US-India healthcare innovation corridor. ReShape Lifesciences’ product offerings address obesity treatment from minimally invasive surgical and non-surgical interventions to investigational bioelectronic devices for metabolic disease. The company targets physicians and healthcare providers offering metabolic and obesity treatment options, with a patient base seeking alternatives to traditional bariatric surgery. Its strategic moves in 2024-2025 reflect a pivot from metabolic health toward leveraging combined strengths in immuno-inflammatory diseases and innovation linking the US and Indian healthcare markets. This represents a significant repositioning within the healthcare sector while maintaining operational presence through subsidiaries and partnerships aligned with new business focuses. The company’s foundation in pioneering weight loss medical devices and ongoing innovations in neuromodulation technology reflect its broader commitment to non-anatomy altering, lifestyle-enhancing therapies for chronic metabolic conditions.
Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation
Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
Vyome Announces New Board of Directors with Deep MIT and AI Ties
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics
ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025
ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System
ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement
ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys
ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology
ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering
ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update
Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
ReShape Lifesciences Announces 1-for-25 Reverse Stock Split
ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System